Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Share-based Compensation (2021 - 2025)

InMed Pharmaceuticals' Share-based Compensation history spans 5 years, with the latest figure at $25564.0 for Q4 2025.

  • For Q4 2025, Share-based Compensation rose 10.38% year-over-year to $25564.0; the TTM value through Dec 2025 reached $22609.0, down 84.55%, while the annual FY2025 figure was $28964.0, 78.97% down from the prior year.
  • Share-based Compensation reached $25564.0 in Q4 2025 per INM's latest filing, up from $20205.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $214779.0 in Q4 2021 to a low of -$63614.0 in Q2 2025.
  • Average Share-based Compensation over 5 years is $66027.5, with a median of $40466.5 recorded in 2023.
  • Peak YoY movement for Share-based Compensation: increased 26.8% in 2024, then plummeted 263.31% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $214779.0 in 2021, then plummeted by 67.11% to $70638.0 in 2022, then tumbled by 74.14% to $18264.0 in 2023, then rose by 26.8% to $23159.0 in 2024, then rose by 10.38% to $25564.0 in 2025.
  • Per Business Quant, the three most recent readings for INM's Share-based Compensation are $25564.0 (Q4 2025), $20205.0 (Q3 2025), and -$63614.0 (Q2 2025).